Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 7/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | POLR1A | O95602 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123153 | 0.85 | POLB (0.47) | POLBPIM1PIM2IRAK4CYP1A2 | |
| SCHEMBL2124369 | 0.85 | POLB (0.47) | POLBPIM1PIM2IRAK4CYP1A2 | |
| SCHEMBL1255754 | 0.72 | POLB (0.49) | POLBPIM1PIM2IRAK4CYP1A2 | |
| SCHEMBL2532937 | 0.72 | KDM4E (0.50) | POLBCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25424532 | 0.71 | KCNK3 (0.52) | — | |
| SCHEMBL4157352 | 0.71 | MEN1 (0.40) | POLB | |
| SCHEMBL25424169 | 0.71 | KDM4E (0.57) | POLB | |
| SCHEMBL15557994 | 0.70 | KDM4E (0.48) | POLB | |
| SCHEMBL2514924 | 0.69 | POLB (0.43) | POLBPIM1PIM2CYP1A2CYP3A4 | |
| SCHEMBL7856603 | 0.69 | POLB (0.43) | POLBPIM1PIM2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2009003993-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095034-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, GPR119 | POLB 4371/4885PIM1 3521/4885PIM2 3203/4885 |
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | POLB 1998/4885PIM1 1476/4885PIM2 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.